IDEXX Laboratories Inc
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 8 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 95.84% -0.07pp
- Institutions
- 1,622 -8
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Jonathan Mazelsky | Executive Chairperson | 0.11% |
| Brian McKeon | Former Executive VP & Special Advisor | 0.03% |
| Nimrata Hunt | Former Executive Vice President of Global Strategy & Commercial | 0.02% |
| Michael Erickson | Chief Executive Officer | 0.02% |
| George Fennell | Executive Vice President of Global CAG Commercial | 0.02% |
| Lawrence Kingsley | Lead Independent Director | 0.01% |
| Sophie Vandebroek | Independent Director | 0.01% |
| Sharon Underberg | Executive VP, General Counsel, & Corporate Secretary | 0.01% |
| Andrew Emerson | Chief Financial Officer | 0.01% |
| Michael Lane | Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | George Fennell | Executive Vice President of Global CAG Commercial | Derivative Exercise and Retained | +1,749 | $141.60–206.94 |
| 2026-11-03 | Daniel Junius | Independent Director | Open Market Disposition | -1,200 | $701.69–705.78 |
| 2026-11-03 | Daniel Junius | Independent Director | Intent to Sell (Form 144) | -1,200 | $691.67–705.78 |
| 2026-11-03 | Sharon Underberg | Executive VP, General Counsel, & Corporate Secretary | Derivative Exercise and Sale | -8,906 | $288.78–690.02 |
| 2026-11-03 | Jonathan Mazelsky | Executive Chairperson | Derivative Exercise and Sale | -25,140 | $178.26–711.95 |
| 2026-11-03 | Michael Lane | Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | Open Market Disposition | -3,978 | $687.46–689.70 |
| 2026-10-29 | Joseph Hooley | Independent Director | Other Acquisition | +48 | $551.21 |
| 2026-09-03 | Lawrence Kingsley | Lead Independent Director | Derivative Exercise and Sale | -2,203 | $114.17–532.08 |
| 2026-08-19 | Andrew Emerson | Chief Financial Officer | Derivative Exercise and Sale | -86 | $178.26 |
| 2026-08-19 | Andrew Emerson | Chief Financial Officer | Derivative Exercise and Retained | +179 | $178.26 |
| 2026-07-29 | Joseph Hooley | Independent Director | Other Acquisition | +49 | $558.80 |
| 2026-05-31 | George Fennell | Executive Vice President of Global CAG Commercial | Derivative Exercise and Sale | -284 | $566.79 |
| 2026-05-31 | George Fennell | Executive Vice President of Global CAG Commercial | Derivative Exercise and Retained | +355 | -- |
| 2026-05-11 | Daniel Junius | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Daniel Junius | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Bruce Claflin | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Bruce Claflin | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Stuart Essig | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Stuart Essig | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Joseph Hooley | Independent Director | Other Derivative Acquisition | +234 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:16 · For reference only, not investment advice and not tailored to your situation.
IDEXX Laboratories Inc discussion 0 comments